• general@orthocell.com
  • +61 8 9360 2888
Orthocell
  • Home
  • About
  • Team
  • Products
  • Invest
  • News
  • Practitioners
    • Striate+â„¢
    • Remplirâ„¢
    • OrthoACIâ„¢
    • Tendon
  • Contact
  • Region
    • Visit AU – Home
    • Visit Americas
    • Visit EU/UK
  • Home
  • About
  • Team
  • Products
  • Invest
  • News
  • Practitioners
    • Striate+â„¢
    • Remplirâ„¢
    • OrthoACIâ„¢
    • Tendon
  • Contact
  • Region
    • Visit AU – Home
    • Visit Americas
    • Visit EU/UK
30 Sep 2022
Orthocell Media Permalink

Stockhead Investor Guide | September 2022

Orthocell 30 September 2022

Orthocell was featured in the widely read column, Dr Boreham’s Crucible, written by respected small cap analyst and business journalist, Tim Boreham. 

Read more

29 Sep 2022
Orthocell Company News Permalink

Ortho-ATIâ„¢ Shoulder Tendon Study Update

Orthocell 29 September 2022

Orthocell has today shared positive results from the crossover extension arm of our randomised clinical trial examining the performance of our OrthoATIâ„¢ therapy in the treatment of rotator cuff tendon injuries, compared to a steroid injection.

Read more

27 Sep 2022
Orthocell Company News Permalink

First orders for dental and nerve products 

Orthocell 27 September 2022

Orthocell has now received first purchase orders for our flagship collagen medical device products Striate+â„¢ and Remplir, via our valued distribution partners.

Read more

13 Sep 2022
Orthocell Audio, Media Permalink

Beyond the Medicine Cabinet Podcast | September 2022

Orthocell 13 September 2022

Orthocell’s CEO and Managing Director Paul Anderson has featured on Beyond The Medicine Cabinet podcast to talk about regenerative nerve repair, and how Orthocell’s Remplir™ collagen nerve wrap is revolutionising surgery for patients with peripheral nerve injuries.

Read more

07 Sep 2022
Orthocell Media, Video Permalink

VIDEO | Proactive Investors – September 2022

Orthocell 7 September 2022

Orthocell’s Paul Anderson spoke with Andrew Scott at Proactive Investors to discuss to discuss the announcement that the Company had secured Device Technologies as the exclusive distribution partner for Remplir™ in the Australian marketplace. 

Read more

07 Sep 2022
Orthocell Media, Video Permalink

Orthocell appoints Device Technologies as distributor of its nerve repair device in Aus, NZ

Orthocell 7 September 2022

Orthocell’s distribution deal with Device Technologies has been featured in The West Australian, in this news article by business reporter Cheyanne Enciso.

Read more

07 Sep 2022
Orthocell Company News Permalink

Appointment of exclusive distributor of Remplirâ„¢ in Australia

Orthocell 7 September 2022

Orthocell has appointed Device Technologies as the exclusive distributor of Remplir™ for peripheral nerve repair in Australia. 

Read more

22 Jul 2022
Orthocell Media, Video Permalink

VIDEO | Proactive Investors – July 2022

Orthocell 22 July 2022

Orthocell’s Paul Anderson spoke with Alisha Newell at Proactive Investors to discuss the Company’s strong position following the recently executed global exclusive licence and distribution agreement with BioHorizons Implant Systems Inc for $OCC’s Striate+™ dental membrane.

Read more

22 Jul 2022
Orthocell Media Permalink

Dr Boreham’s Crucible | July 2022

Orthocell 22 July 2022

Orthocell was featured in the widely read column, Dr Boreham’s Crucible, written by respected small cap analyst and business journalist, Tim Boreham. 

Read more

08 Jul 2022
Orthocell Media, Video Permalink

VIDEO | ShareCafe ‘Hidden Gems’ Webinar – July 2022

Orthocell 8 July 2022

Orthocell CEO and Managing Director, Paul Anderson, recently participated in the ShareCafe Small Cap ‘Hidden Gems’ Webinar.

Read more

  • Recent posts

    • Orthocell Secures Health Canada Approval for Remplirâ„¢ in US$75 million Canadian Market
    • Orthocell Receives Regulatory Approval to Commence Sales of Remplirâ„¢ in US$84 million Thai market
    • Orthocell Appoints its First Four US Remplirâ„¢ Distributors
    • AusBiz | Interview with John Van Der Wielen
    • Orthocell Receives Regulatory Approval for Striate+ in Brazil
Previous
Next
  • © Orthocell Ltd. All rights reserved.

  • Contact Us

  • P: +61 8 9360 2888
    F: +61 8 9360 2899
    E: general@orthocell.com

  • News Updates

  • By entering your email address you are agreeing to our privacy policy.

BUILT WITH ♡ BY H^CK Orthocell POWERED BY United Themes™
Please select the country you would like to view

Visit AU – Home

Visit Americas

Visit EU/UK

Join our mailing list

    By entering your email address you are agreeing to our privacy policy.


    Sign up to our EDM

    By entering your email address you are agreeing to our privacy policy.

    Patient expression of interest